The FDA approved a heart valve that can be widened as a child grows
In a study of 62 children, the Autus valve met the FDA's six-month bar. Only two have been expanded so far, and longer follow-up is still underway.

Read the original
The reporting lives at U.S. Food and Drug Administration. Our summary is checked against it, and we link it on every story.
The Food and Drug Administration said on October 1, 2026, that it approved the Autus Size-Adjustable Valve for children with congenital pulmonary valve disease. Surgeons can implant it at about 13 millimeters, a size meant for a toddler or preschooler, and later widen it with a balloon catheter up to about 22 millimeters. It is also the first valve the agency has approved with inner flaps made of a polymer instead of animal tissue.
The decision uses a study of 62 children at 12 sites in the United States. At six months, the first 60 had blood flow the FDA called acceptable, with no more than mild leakage back through the valve. Every procedure succeeded. There were no deaths, no strokes, and no blood clots that needed more treatment. Three valve frames fractured and two flaps moved less than they should. None of those events caused symptoms. Two children began to outgrow the valve, and both had it expanded without another open-heart surgery. The FDA said that experience is limited and that longer studies are still going. The valve may mean fewer open-heart operations. The study has not shown that yet.
Health & Tech in MarylandSilver Spring, MarylandMedical researchKidsGood news on October 1
More good news
Other stories in the same neighborhood of kindness.
Health & TechFDA approves Livsayis, a four-times-a-year shot for myasthenia gravis
Livsayis is the first siRNA drug for anti-AChR-positive generalized myasthenia gravis. In a 24-week trial, 77 percent of adults improved on daily-living scores, compared with 44 percent on placebo. It carries a meningococcal infection warning.
Verified · WebMD
Health & TechFDA approves the first drug for the neurological symptoms of Type 3 Gaucher disease
Infilbray, a daily pill that reaches the brain, improved a combined coordination and thinking score versus enzyme infusions in a 52-week trial of 43 patients. Survival was not the measure.
Verified · U.S. FDA
Health & TechThe FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.
Verified · U.S. Food and Drug Administration